跳至主要内容
临床试验/NCT02611414
NCT02611414Unknown2 期

Effectiveness of Transcranial Direct Current Stimulation for the Treatment of Functional Dyspepsia: a Randomized Controlled Trial

Hospital Ernesto Dornelles2 个研究点 分布在 1 个国家目标入组 70 人开始时间: 2016年1月最近更新:
适应症

试验速览

阶段
2 期
入组人数
70
试验地点
2
主要终点
PADYQ score

研究概览

简要总结

Functional dyspepsia is a very common disorder of great challenge to clinical management. A therapeutic targets is up-regulation of visceral pain threshold. The transcranial direct current stimulation (tDCS) is a novel therapy that pursues these properties, besides its safety and easy adherence. There is a great need of new treatments for functional dyspepsia. There is no current study evaluating tDCS for this disease.

详细描述

Functional dyspepsia is a high prevalent disease with substantial costs to health system. There are many available treatments, but disappointing results are reported in clinical trials.

TDCS is a noninvasive, secure and painless technique of brain stimulation. It is delivered by a battery-operated device that transfers low intensity electrical current to all surface of the brain. Then there is a modulation of cortical excitability and influence on central neurological functions. It has been reported its efficacy for the treatment of many diseases such as depression and chronic pain.

Impairment of central mechanisms of interpretation and threshold of pain are related to functional dyspepsia. Therefore, tDCS may benefit dyspeptic patients.

This study is a double blind randomized controled trial to test tDCS effectiveness on functional dyspepsia. Seventy functional dyspeptic patients will be enrolled, being randomized to either tDCS or sham tDCS.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • functional dyspeptic patients according to Rome IV criteria
  • clinical investigation reporting absence of organic causes of functional dyspepsia
  • Exclusion Criteria
  • history of brain trauma, haemorrhage or ischemia
  • implantable devices such as pacemaker
  • alcohol or drug abuse
  • severe chronic disease
  • non-acceptance to sign up the term of consent.

排除标准

  • 未提供

结局指标

主要结局

PADYQ score

时间窗: 4 weeks

Decrease in PADYQ (Porto Alegre Dyspepsia Symptoms Questionnaire) score

次要结局

  • HADS score(4 weeks)
  • SF36 score(4 weeks)
  • Use of drugs for dyspeptic symptoms(1 and 4 weeks)
  • Self-reported treatment response(1 and 4 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Carine Leite

Carine Leite, MD

Hospital Ernesto Dornelles

研究点 (2)

Loading locations...

相似试验